Publications

NASOVAC-S4 is a quadrivalent vaccine which has evolved from a decade long legacy of NASOVAC-S & NASOVAC. NASOVAC was developed by Serum Institute during the 2009-2010 H1N1 pandemic. NASOVAC was a monovalent H1N1 vaccine which was administered to more than 2.5 million individuals during the pandemic. NASOVAC-S is a trivalent vaccine that evolved from NASOVAC, which was the precursor to NASOVAC-S4.

NASOVAC-S4 is essentially the same as trivalent NASOVAC-S of SIIPL since the same master donor virus is used except for the presence of an additional B strain & a liquid presentation. Hence, the immunogenicity, efficacy and safety data of earlier live attenuated influenza virus vaccines of SIIPL are applicable to Quadrivalent Influenza Vaccine.

A pandemic influenza vaccine in India: From strain to sale within 12 months.

Efficacy of live attenuated and inactivated influenza vaccines among children in rural India: A 2-year, randomized, triple-blind, placebo-controlled trial.

Safety of Russian-Backbone Trivalent, Live Attenuated Seasonal Influenza Vaccine in Healthy Subjects: Open-Label, Non-randomized Phase 4 Study.

Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh.

Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomized, double-blind, placebo-controlled trial.